Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.63 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | TET3 | O43151 | 1/20 | 0.46 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.46 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.46 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.46 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.46 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10571417 | 0.84 | HDAC9 (0.67) | AKR1C1HDAC9HDAC4KMT2ATET3 | |
| SCHEMBL13226486 | 0.84 | AKR1C1 (0.60) | AKR1C1HDAC9HDAC4KMT2ATET3 | |
| SCHEMBL15215650 | 0.83 | AKR1C1 (0.48) | AKR1C1HDAC9HDAC4KMT2AHSD11B1 | |
| SCHEMBL28304679 | 0.83 | AKR1C1 (0.48) | AKR1C1HDAC9HDAC4KMT2AHSD11B1 | |
| SCHEMBL8110659 | 0.83 | AKR1C1 (0.59) | AKR1C1HDAC9HDAC4KMT2ATET3 | |
| SCHEMBL31016196 | 0.81 | AKR1C1 (0.83) | AKR1C1HDAC9HDAC4KMT2ATET3 | |
| SCHEMBL6391 | 0.81 | AKR1C1 (0.83) | AKR1C1HDAC9HDAC4KMT2ATET3 | |
| SCHEMBL31292256 | 0.81 | APP (0.46) | AKR1C1KMT2AHSD11B1MEN1CYP2C9 | |
| SCHEMBL631791 | 0.81 | AKR1C1 (0.68) | AKR1C1HDAC4KMT2ATET3FBXL19 | |
| SCHEMBL25460743 | 0.81 | AKR1C1 (0.52) | AKR1C1HDAC9HDAC4KMT2ATET3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| EP-3408256-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | Takeda Pharmaceutical Company Limited (JP) | 2018-12-05 | — | — | EP | disclosed |
| EP-3292118-A1 | AMINOESTER DERIVATIVES | Chiesi Farmaceutici S.p.A. (IT) | 2018-03-14 | — | — | EP | disclosed |
| US-20180016265-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-01-18 | — | — | US | disclosed |
| US-9809582-B2 | Aminoester derivatives | CHIESI FARMACEUTICI S.P.A. (IT) | 2017-11-07 | — | — | US | disclosed |
| WO-2017131221-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | WO | disclosed |
| WO-2016177849-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-11-10 | — | — | WO | disclosed |
| US-20160326147-A1 | AMINOESTER DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2016-11-10 | — | — | US | disclosed |
| US-7553841-B2 | Amino cyclobutylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553841-B2 | Amino cyclobutylamide modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-6124354-A | TREATMENT OF URINARY INCONTINENCE OR IRRITABLE BOWEL SYNDROME | PHARMACIA & UPJOHN AB (SE) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016265-A1 | AMINOESTER DERIVATIVES | PDE4A, PDE3A, PDE3B | AKR1C1 461/4885HDAC9 1662/4885HDAC4 669/4885 |
| US-20160326147-A1 | AMINOESTER DERIVATIVES | PDE4A, PDE3A, PDE3B | AKR1C1 461/4885HDAC9 1662/4885HDAC4 669/4885 |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | GRM7, GRIN2B, GRM1 | AKR1C1 4515/4885HDAC9 1588/4885HDAC4 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.